Navigation Links
Advanced Life Sciences Announces Second Quarter 2009 Financial Results and Financial Outlook
Date:8/11/2009

CHICAGO, Aug. 11 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced its financial results for the second quarter ended June 30, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080218/ALSLOGO)

The net loss allocable to common shareholders for the three months ended June 30, 2009 was $2.6 million or ($0.06) per share compared to a net loss allocable to common shareholders of $3.4 million or ($0.09) per share for the three months ended June 30, 2008. The decrease in the net loss is due to decreased costs involved in the clinical development of the Company's lead compound, Restanza(TM) (cethromycin).

The Company ended the second quarter of 2009 with cash and cash equivalents totaling $1.0 million. Cash used during the quarter was approximately $2.9 million.

"Advanced Life Sciences today is focused on continuing to pursue approval for Restanza in community acquired pneumonia or CAP and complying with the recommendations by the FDA concerning next steps that can lead to a registration pathway," said Michael T. Flavin, Ph.D., chairman and chief executive officer of Advanced Life Sciences. "Based on the agency's recent communication with the Company, we anticipate that an additional well-controlled clinical study designed to demonstrate efficacy in a more severe CAP population will likely be required for the approval of Restanza. We intend to work closely with the agency to design and establish a protocol under a Special Protocol Assessment. We are working on these clinical plans with Wyeth, our development and commercialization partner in the Asia
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels
2. Advanced Life Sciences to Host 2009 Second Quarter Financial Results Conference Call and Webcast
3. Next Safety Releases Advanced Respirator for Infectious Diseases
4. Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia
5. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
6. Enerkem Announces World-Class Advanced Energy Research Center in Edmonton, Alberta, Canada
7. Unexpectedly long-range effects in advanced magnetic devices
8. UCF teams advanced nerve cell system could help cure diabetic neuropathy, related diseases
9. Advanced Life Sciences Restanza(TM) Shows 100% Survival In Confirmatory Anthrax Study
10. Visage Imaging to Provide Visage(R) CS Enterprise Wide Advanced Visualization Solutions to Advanced Radiology Consultants
11. Abbott & BioGenex Extend the Technology Co-development and Distribution Agreement for Marketing the Xmatrx(R) Advanced Staining Platform for the Automation of FISH, IHC and ISH Molecular Diagnostic Assays
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... NEW PROVIDENCE, N.J. , Sept. 2, 2014 /PRNewswire/ ... sponsor for MassBio,s 20th Annual Golf Classic, a major ... The event will be held on September 5 at ... Massachusetts . The MassBioEd Foundation ... through educational programs, workforce development, and lifelong ...
(Date:9/2/2014)... a billionth of a meter in size, are around ... benefit human health, as in some innovative early cancer ... viruses, air pollution, traffic emissions, cosmetics, sunscreen and electronics. ... St. Louis, led by Lan Yang, PhD, the Das ... Engineering, and their collaborators at Tsinghua University in China ...
(Date:9/2/2014)... including University of Oregon chemist Geraldine Richmond, have ... self-assembling, synthetic proteins called peptoid nanosheets that mimic ... -- detailed this week in a paper placed ... of the National Academy of Sciences -- ... the two-dimensional peptoid nanosheets that can be used ...
(Date:9/2/2014)... NEW YORK , September 2, 2014 ... Market Study on Membrane Technology in Pharmaceutical, Biopharma and ... Witness Highest Growth by 2019" the global membrane technology market for ... 7,029.9 million in 2014 and is expected to grow ... to reach an estimated value of USD 10,886.0 million ...
Breaking Biology Technology:Linde helps fund STEM education in Massachusetts 2Linde helps fund STEM education in Massachusetts 3Engineers develop new sensor to detect tiny individual nanoparticles 2Engineers develop new sensor to detect tiny individual nanoparticles 3UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5
... ... ... var shortURL ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for ...
... ... ... var shortURL = ""; BitlyCB.alertResponse ... grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in ...
... in a row, a pair of Rensselaer students took ... held by the American Society of Mechanical Engineers (ASME). ... Jaron Kuppers won top honors in the national competition ... process. The SET process offers a new method for ...
Cached Biology Technology:YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 2YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 3YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 4YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 5YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 6YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 7YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 8YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387 9Medivir: R&D Day 2Medivir: R&D Day 3Medivir: R&D Day 4Medivir: R&D Day 5Medivir: R&D Day 6Medivir: R&D Day 7Medivir: R&D Day 8Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 2Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 3Rensselaer mechanical engineers win first place at ASME student manufacturing design competition 4
(Date:9/2/2014)... Cancer Center researchers may have discovered a new way ... vulnerable by deficient DNA repair. , The findings were ... , The study, led by James E. Hansen, ... of Medicine, found that cancer cells with deficient DNA ... genetic damage) were significantly more vulnerable to attack by ...
(Date:9/2/2014)... FL, September 2, 2014 In a new study ... from the Florida campus of The Scripps Research Institute ... cells into unique manufacturing sites for molecules that can ... a cell as a reaction vessel and a disease-causing ... a diseased cell," said TSRI Professor Matthew Disney.,"Because the ...
(Date:9/2/2014)... sequence their genetic information. How is it possible ... parts of the body are so different? While every ... additional regulatory layer exists that determines which of the ... modifications of genome-bound histone proteins or the DNA itself ... top of the genetic information and is thus called ...
Breaking Biology News(10 mins):Sabotage as therapy: Aiming lupus antibodies at vulnerable cancer cells 2Scripps Florida scientists make diseased cells synthesize their own drug 2Throwing a loop to silence gene expression 2
... assessment of malnutrition, created by researchers at Penn State, ... diagnosis and treatment. Up to 50 percent of ... be malnourished, according to Gordon Jensen, professor and head ... confusion exists in the clinical community on how to ...
... seeking to refine and improve lung-cancer screening by combining a ... more effectively. The trial combines a CT chest scan and ... to build on recent research demonstrating that CT screening alone ... CT screening of high-risk patients can reduce lung-cancer deaths. But ...
... heel within our cells that bacteria are able to exploit ... their findings could lead to the development of new anti-infective ... resistance. University of Manchester researchers studied Listeria ... listeriosis in humans when digested and found they are ...
Cached Biology News:Researchers unveil new assessment for diagnosing malnutrition 2Trial seeks improved lung-cancer screening by combining imaging and biomarkers 2
Kit for testing the ability of a compound to simulate lipolysis in cultured human adipocytes. Kit contains controls, buffers and reagents for detecting glycerol and non-esterified free fatty acids. A...
... The Experion Pro260 analysis kit for 10 ... to perform protein analysis with the Experion ... Pro260 microfluidic chips, 3 x 520 microliters ... microliters Pro260 ladder (10-260 kD), 400 microliters ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... Staccato Mini-Workstations provide fast and reliable ... proteomics and drug development laboratories. Staccato ... instrumentation to automate basic liquid handling ... are controlled with either Caliper's time ...
Biology Products: